The value assessment of cancer medicines must account for how trials have changed

Sponsored content on POLITICO is created or curated by advertisers, such as Gilead Sciences, and is presented alongside editorial material. This content is clearly labeled as 'sponsor-generated' to distinguish it from regular articles, ensuring transparency about its origin. The editorial team at POLITICO does not participate in the production of this sponsored content.